Antibodies are our body’s natural defense against disease. Therapeutic antibodies, widely used for conditions like cancer and arthritis, are typically derived from animals. MEMO Therapeutics is changing this by isolating antibodies directly from humans with strong immune responses, offering a new path for advanced treatments.
However, isolating human antibodies is highly inefficient due to the fragility of B-cells—the immune cells responsible for producing antibodies. These cells often die during the isolation process, especially in donors with health conditions.
MEMO Therapeutics has developed a groundbreaking method to overcome this challenge. Their technology captures and preserves B-cells efficiently, digitizing the entire human antibody repertoire. This makes it possible to search and utilize human antibodies for drug discovery, accelerating the development of novel therapies.
The process starts by isolating B-cells from individuals who have recovered from specific diseases. Each B-cell is encapsulated in a microscopic droplet, preserving its function while enabling high-throughput DNA extraction. This data is stored in a library, allowing researchers to analyze and select the most promising antibodies. These selected antibodies are then transferred into stable cell lines for further testing and therapeutic development.
By making human antibody discovery faster and more precise, MEMO Therapeutics is paving the way for next-generation medicines. Learn more at MEMO Therapeutics.
